BioCryst Pharmaceuticals Newsroom

BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating

Moomoo NewsNov 14 10:31 ET

BioCryst Pharmaceuticals Price Target Maintained With a $14.00/Share by Needham

Dow JonesNov 5 10:00 ET

BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays

Dow JonesNov 5 08:50 ET

BioCryst Pharma Analyst Ratings

BenzingaNov 5 08:41 ET

RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsNov 5 08:33 ET

Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsNov 5 08:31 ET

A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $8 to $30

Moomoo NewsNov 5 08:07 ET

Piper Sandler Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsOct 23 08:31 ET

JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsOct 2 10:33 ET

Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsAug 7 00:32 ET

BioCryst Pharmaceuticals Price Target Raised to $16.00/Share From $15.00 by JMP Securities

Dow JonesAug 6 13:14 ET

A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $10 to $30

Moomoo NewsAug 6 09:00 ET

Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $7

BenzingaAug 6 08:54 ET

BioCryst Pharmaceuticals: A Buy Rating Anchored on Orladeyo's Success and Expansion in Rare Disease Treatments

TipRanksAug 6 06:39 ET

BioCryst Pharma Analyst Ratings

BenzingaAug 6 06:33 ET

BioCryst Pharmaceuticals: Strong Orladeyo Sales and Promising Pipeline Justify Buy Rating

TipRanksAug 5 15:09 ET

Piper Sandler Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $20

Moomoo NewsJul 23 07:42 ET

BioCryst (BCRX) Receives a Buy From RBC Capital

TipRanksMay 7 08:10 ET

BioCryst Pharma Analyst Ratings

BenzingaMay 7 05:34 ET

BioCryst Pharma Analyst Ratings

BenzingaApr 10 07:11 ET